Interference No. 103,675
30347-066; a proposed empirical formula; the weight of the sample;
identification of the sample as a taxol derivative which was a 1:1
mixture of epimeric fluorides at C7 and, a proposed utility
("Antitumor Agent"). Linda Kissel, a Bristol-Myers Squibb employee in
the Compound Control Department, filled out the top part of the form
(Part 1), including the formula and molecular weight as determined by
a computer and based on the proposed structure furnished by Drs. Chen
and Farina.
After the sample and the form were submitted, Dr. Mamber
performed a tubulin polymerization assay on BMS-46546. Based on the
test results for the compounds Dr. Mamber testified that he informed
Drs. Chen and Farina of the results (CR 125, line 16 through CR 126,
line 12; CX 172). Dr. Mamber retested BMS-46546 two more times in
November 1990 using the same procedure which tests confirmed his
earlier results (CR 126). Dr. Chen included the results of the testing
in the Quarterly Report he prepared for Dr. Vayas (CX 17). Dr. Mamber
did not testify as to the identity of the sample he tested other than
stating that it was the sample he received from Drs. Chen and Farina.
In November 1990, BMS-46546 was also tested for in vitro
cytotoxicity (CR 132,134). The results of the testing were comparable
to the results for the taxol control also tested along with the sample
of BMS-46546 (CR 136). The results were provided to Dr. Chen and Dr.
105
Page: Previous 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 Next
Last modified: November 3, 2007